{"id":35827,"date":"2025-08-06T17:31:57","date_gmt":"2025-08-06T21:31:57","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&p=35827"},"modified":"2025-08-06T17:32:04","modified_gmt":"2025-08-06T21:32:04","slug":"paolo-bossi-md","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/paolo-bossi-md","title":{"rendered":"Paolo Bossi, MD"},"content":{"rendered":"\n

Some mouth lesions, known as oral potentially malignant disorders (OPMDs), carry a significant risk of becoming cancerous \u2013 ranging from 1% to nearly 50%. Even after surgical removal, many of these lesions can still progress to cancer. Dr. Paolo Bossi and colleagues will test a new immunotherapy-based approach to stop that transformation before it happens. <\/p>\n\n\n\n

The APHRODITE Trial focuses on mitazalimab, an immune-stimulating, \u201corphan\u201d drug that activates a pathway called CD40, which plays a key role in immune surveillance and tumor prevention. In this phase II trial, patients with high-risk OPMDs will receive mitazalimab over an eight-week period. After six months, the team will assess whether the treatment reduced or eliminated abnormal tissue and evaluate its safety, impact on cancer risk, and effects on quality of life.<\/p>\n\n\n\n

The study will also analyze blood, tissue, and saliva samples to understand how the immune system and microbiome respond to treatment, insights that could help identify which patients are most likely to benefit. If successful, this approach could offer a less invasive, immunotherapy-based alternative to surgery and transform care for patients with pre-cancerous oral lesions.<\/p>\n\n\n\n

In addition to IRCCS Humanitas Research Hospital, clinical trial sites include ASST Santi Paolo e Carlo, European Institute of Oncology, ASST Sette Laghi, ASST Lariana, Federico II University,
and the University of Bologna.<\/p>\n\n\n\n

Projects and Grants<\/h2>\n\n\n\n

Immunotherapy for the prevention of high-risk oral disorders malignant transformation – The APHRODITE Trial<\/strong><\/h3>\n\n\n\n

Co-Investigators<\/h2>\n\n\n\n
    \n
  • Luigi Lorini, MD<\/li>\n\n\n\n
  • Enrico Lugli, PhD<\/li>\n\n\n\n
  • Giuseppe Mercante, MD<\/li>\n\n\n\n
  • Alberto Paderno, MD, PhD<\/li>\n\n\n\n
  • Maria Rescigno, PhD<\/li>\n<\/ul>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    Some mouth lesions, known as oral potentially malignant disorders (OPMDs), carry a significant risk of becoming cancerous \u2013 ranging from 1% to nearly 50%. Even after surgical removal, many of these lesions […]<\/p>\n","protected":false},"featured_media":35829,"template":"","tax_cancer_type":[355],"tax_grant_type":[725],"tax_award_year":[742],"tax_institutions":[869],"tax_location_states":[503],"class_list":["post-35827","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"CRI Clinical Innovator","quote":"","scientist_last_name":"Bhardwaj","show_on_landing":false,"scientist_publish_until":"20280831"},"yoast_head":"\nPaolo Bossi, MD - Cancer Research Institute<\/title>\n<meta name=\"description\" content=\"The APHRODITE Trial focuses on mitazalimab, an immune-stimulating, \u201corphan\u201d drug that activates a pathway called CD40, which plays a key role in immune surveillance and tumor prevention. In this phase II trial, patients with high-risk OPMDs will receive mitazalimab over an eight-week period. After six months, the team will assess whether the treatment reduced or eliminated abnormal tissue and evaluate its safety, impact on cancer risk, and effects on quality of life.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Paolo Bossi, MD - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"The APHRODITE Trial focuses on mitazalimab, an immune-stimulating, \u201corphan\u201d drug that activates a pathway called CD40, which plays a key role in immune surveillance and tumor prevention. In this phase II trial, patients with high-risk OPMDs will receive mitazalimab over an eight-week period. After six months, the team will assess whether the treatment reduced or eliminated abnormal tissue and evaluate its safety, impact on cancer risk, and effects on quality of life.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-06T21:32:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"732\" \/>\n\t<meta property=\"og:image:height\" content=\"529\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md\",\"url\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md\",\"name\":\"Paolo Bossi, MD - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg\",\"datePublished\":\"2025-08-06T21:31:57+00:00\",\"dateModified\":\"2025-08-06T21:32:04+00:00\",\"description\":\"The APHRODITE Trial focuses on mitazalimab, an immune-stimulating, \u201corphan\u201d drug that activates a pathway called CD40, which plays a key role in immune surveillance and tumor prevention. In this phase II trial, patients with high-risk OPMDs will receive mitazalimab over an eight-week period. After six months, the team will assess whether the treatment reduced or eliminated abnormal tissue and evaluate its safety, impact on cancer risk, and effects on quality of life.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg\",\"width\":732,\"height\":529},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Paolo Bossi, MD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Paolo Bossi, MD - Cancer Research Institute","description":"The APHRODITE Trial focuses on mitazalimab, an immune-stimulating, \u201corphan\u201d drug that activates a pathway called CD40, which plays a key role in immune surveillance and tumor prevention. In this phase II trial, patients with high-risk OPMDs will receive mitazalimab over an eight-week period. After six months, the team will assess whether the treatment reduced or eliminated abnormal tissue and evaluate its safety, impact on cancer risk, and effects on quality of life.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md","og_locale":"es_ES","og_type":"article","og_title":"Paolo Bossi, MD - Cancer Research Institute","og_description":"The APHRODITE Trial focuses on mitazalimab, an immune-stimulating, \u201corphan\u201d drug that activates a pathway called CD40, which plays a key role in immune surveillance and tumor prevention. In this phase II trial, patients with high-risk OPMDs will receive mitazalimab over an eight-week period. After six months, the team will assess whether the treatment reduced or eliminated abnormal tissue and evaluate its safety, impact on cancer risk, and effects on quality of life.","og_url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md","og_site_name":"Cancer Research Institute","article_modified_time":"2025-08-06T21:32:04+00:00","og_image":[{"width":732,"height":529,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md","url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md","name":"Paolo Bossi, MD - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg","datePublished":"2025-08-06T21:31:57+00:00","dateModified":"2025-08-06T21:32:04+00:00","description":"The APHRODITE Trial focuses on mitazalimab, an immune-stimulating, \u201corphan\u201d drug that activates a pathway called CD40, which plays a key role in immune surveillance and tumor prevention. In this phase II trial, patients with high-risk OPMDs will receive mitazalimab over an eight-week period. After six months, the team will assess whether the treatment reduced or eliminated abnormal tissue and evaluate its safety, impact on cancer risk, and effects on quality of life.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg","width":732,"height":529},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/paolo-bossi-md#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Paolo Bossi, MD"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"fimg_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg","_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists\/35827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_scientists"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/35829"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=35827"}],"wp:term":[{"taxonomy":"tax_cancer_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_cancer_type?post=35827"},{"taxonomy":"tax_grant_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_grant_type?post=35827"},{"taxonomy":"tax_award_year","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_award_year?post=35827"},{"taxonomy":"tax_institutions","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_institutions?post=35827"},{"taxonomy":"tax_location_states","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_location_states?post=35827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}